RxDoctor Payments Data

Amanda Hatcher

Family · Bassett, VANPI 1679183115

Payments from drug & device makers

$1,145in general payments, 2019–2025

Across 64 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$289
  • Novo Nordisk$182
  • Corcept Therapeutics$137
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$126
  • Xeris Pharmaceuticals, Inc.$71
  • Amgen$61
  • plus $279 from 13 others

What the payments were for

  • Food & beverage$1,145100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,145 in reported general payments places this provider in the 70th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$266
Medicare patients
23
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide85$88,493
FarxigaDapagliflozin Propanediol48$44,903
MounjaroTirzepatide30$35,665
OzempicSemaglutide31$34,589
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31$22,303
JanuviaSitagliptin Phosphate30$21,330
EliquisApixaban26$18,693
LinzessLinaclotide17$13,469
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,230
Tresiba Flextouch U-100Insulin Degludec15$12,847
Breo ElliptaFluticasone/Vilanterol26$11,171
Levemir FlexpenInsulin Detemir33$6,848
Novolog FlexpenInsulin Aspart36$6,318
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$4,408
Albuterol Sulfate HfaAlbuterol Sulfate149$4,258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$29$125,307135 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$18$61,12580 claims
Novo NordiskOzempic$182$34,58931 claims
MerckJanuvia$21$21,33030 claims
AbbVieLinzess$289$13,46917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,332 family providers in Virginia.

Other family in Bassett

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →